A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report

Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy characterized by a poor prognosis, with a median survival time of approximately 3 to 4 months. In this report, we present a case involving a 59-year-old patient diagnosed with ATC, who experienced swift local recurrence an...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Ming Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
anaplastic thyroid carcinoma
PD-1 inhibitor
PD-L1 expression level
whole exome sequencing
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544604/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items